Cancer News and Research

Latest Cancer News and Research

Lapatinib plus trastuzumab extend lives of HER2-positive breast cancer patients

Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine at Duke University Medical Center.

12 Dec 2009

Enrollment of patients for Phase IIb clinical trial of WBI-1001 commenced

Welichem today announced that the Company has begun to enroll patients in a Phase IIb clinical trial with its lead candidate, WBI-1001. The Phase IIb clinical trial is a double-blinded, placebo-controlled, 12-week-treatment study.

12 Dec 2009

Results from clinical survey of Oncotype DX on patients with node-positive breast cancer announced

Genomic Health, Inc. today announced results from a clinical survey evaluating the impact of the Oncotype DX® Recurrence Score® result on physicians' adjuvant treatment recommendations for patients with node-positive, hormone receptor-positive breast cancer.

12 Dec 2009

Anti-estrogens may reduce the risk of death from lung cancer, according to study results

Anti-estrogens as therapy for breast cancer may also reduce the risk of death from lung cancer, according to study results presented at the CTRC-AACR San Antonio Breast Cancer Symposium, held here Dec. 9-13, 2009.

11 Dec 2009

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML).

11 Dec 2009

HTDS comments on its recent stock price activity

Hard to Treat Diseases (HTDS) http://www.htdsmedical.com the company has been asked to comment on recent activity in its stock price. First, we would like our shareholders to be reassured and take comfort in the fact that there is no news that they do not know about. While there are several significant pending transactions they are not ready to be announced yet, however will be in due and appropriate time.

11 Dec 2009

Zevalin clinical data presented at 2009 ASH meeting

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, today announced that clinical data on ZEVALIN (ibritumomab tiuxetan) was presented at the 51st Annual Meeting of the American Society of Hematology (ASH), which was held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

11 Dec 2009

Genentech terminates dacetuzumab collaboration agreement with Seattle Genetics

Seattle Genetics, Inc. today reported that it has been notified by Genentech, a wholly owned member of the Roche Group, that Genentech has elected to terminate the companies’ collaboration agreement for dacetuzumab (SGN-40). Dacetuzumab is a monoclonal antibody targeting CD40 that has been investigated in clinical trials for non-Hodgkin lymphoma and multiple myeloma.

11 Dec 2009

CyMap technology wins first prize in the Medical and Healthcare category

CyMap, an innovative lens-free microscope developed by Cancer Research UK scientists and members of the Optical Biochips Consortium*, has won first prize in the Medical and Healthcare category of The Engineer's Technology and Innovation Awards as well as the overall Grand Prix prize.

11 Dec 2009

First Edition: December 11, 2009

Today's headlines track the fits and starts of the Senate's health bill debate, including moderates' concern regarding the recent Medicare expansion deal and House Speaker Nancy Pelosi's positive reaction to it. Meanwhile, floor action appears snagged on a drug importation amendment.

11 Dec 2009

Pfizer announces IES analysis of Aromasin in breast cancer recurrence

Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.

11 Dec 2009

University of Maryland School of Nursing to spearhead new Center for Pain Studies

The University of Maryland School of Nursing in Baltimore is "uniquely poised" to spearhead a new collaborative Center for Pain Studies funded by a $2.4 million, five-year federal grant, said Susan Dorsey, PhD, RN, director of the center.

11 Dec 2009

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

Bisphosphonates are routinely given to women with postmenopausal breast cancer, but new data suggests that these agents may play a role in reducing recurrent breast cancer as well.

11 Dec 2009

NCKUH and NHRI sponsor virology lab in Vietnam Children’s Hospital

A Virology Lab in Children’s Hospital No. 1 (CH1), Ho Chi Minh City, Vietnam, sponsored by National Cheng Kung University Hospital (NCKUH) and National Health Research Institutes (NHRI) in Taiwan was launched on November 11th, 2009.

11 Dec 2009

UT researchers identify new molecule that slows ALS progression in mice

Researchers at UT Southwestern Medical Center have found that a molecule produced naturally by muscles in response to nerve damage can reduce symptoms and prolong life in a mouse model of amyotrophic lateral sclerosis (ALS).

11 Dec 2009

African-American women in South Carolina more likely to have cervical cancer than white women

African-American women in South Carolina are 37 percent more likely to have cervical cancer than white women and have a death rate that is about 61 percent higher, according to a study by researchers at the University of South Carolina's Arnold School of Public Health.

11 Dec 2009

Proposed changes to breast cancer screening criticized

The Editor-in-Chief of Cancer Investigation and one of the country's most respected medical policy professors has written a new commentary which criticizes proposed changes to breast cancer screening.

11 Dec 2009

Oconomowoc Memorial Hospital performs partial knee resurfacing surgery using MAKOplasty technology

For the first time in Wisconsin, patients suffering from arthritis pain have access to a new procedure that uses the precision of robotics to perform partial knee resurfacing surgery. The technology, called MAKOplasty®, is a minimally invasive surgical option that results in shorter hospital stays and faster healing than traditional knee surgeries.

11 Dec 2009

Update on proposed transaction that will lead to the merger of Cytopia into YM BioSciences provided

YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today provided an update on the proposed transaction which would result in the merger of Cytopia Ltd. into YM, details of which were announced on October 5, 2009.

11 Dec 2009

ThromboGenics initiates Phase II trial of microplasmin for wet AMD

ThromboGenics NV, a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, announces today that it has started a Phase II trial of microplasmin for the treatment of exudative (wet) Age-related Macular Degeneration (AMD).

11 Dec 2009

Cancer News and Research

Latest Cancer News and Research

Lapatinib plus trastuzumab extend lives of HER2-positive breast cancer patients

Enrollment of patients for Phase IIb clinical trial of WBI-1001 commenced

Results from clinical survey of Oncotype DX on patients with node-positive breast cancer announced

Anti-estrogens may reduce the risk of death from lung cancer, according to study results

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

HTDS comments on its recent stock price activity

Zevalin clinical data presented at 2009 ASH meeting

Genentech terminates dacetuzumab collaboration agreement with Seattle Genetics

CyMap technology wins first prize in the Medical and Healthcare category

First Edition: December 11, 2009

Pfizer announces IES analysis of Aromasin in breast cancer recurrence

University of Maryland School of Nursing to spearhead new Center for Pain Studies

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

NCKUH and NHRI sponsor virology lab in Vietnam Children’s Hospital

UT researchers identify new molecule that slows ALS progression in mice

African-American women in South Carolina more likely to have cervical cancer than white women

Proposed changes to breast cancer screening criticized

Oconomowoc Memorial Hospital performs partial knee resurfacing surgery using MAKOplasty technology

Update on proposed transaction that will lead to the merger of Cytopia into YM BioSciences provided

ThromboGenics initiates Phase II trial of microplasmin for wet AMD

Understanding the DNA Damage Response in Innate Immunity eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in